Who Paid My Doc
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
ClinicalTrials.gov NCT05461573
Research payments
$1,507,330
Through program year 2025, $1,507,330 in research payments was reported against Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females, across 265 payments, paid by Exeltis, USA Inc..
- Paid by
- Exeltis, USA Inc.
- ClinicalTrials.gov
- NCT05461573
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,507,330 | 265 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Janet Gersten Miami, FL Named on 23 payments
- Jeffrey Baker Idaho Falls, ID Named on 18 payments
- Catherine Brainard Tucson, AZ Named on 14 payments
- Jude Acloque Boynton Beach, FL Named on 12 payments
- Valentin Almendarez San Antonio, TX Named on 11 payments
- Ann Collins Raleigh, NC Named on 11 payments
- Gerard Acloque Hollywood, FL Named on 9 payments
- Brandon Perez Marrero, LA Named on 9 payments
- George Herrera Doral, FL Named on 9 payments
- Rafael Garcia-Ocasio Hialeah, FL Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.